Briacell Therap (NASDAQ:BCTX) Issues Quarterly Earnings Results

Briacell Therap (NASDAQ:BCTX) announced its quarterly earnings results on Tuesday. The company reported ($0.99) earnings per share (EPS) for the quarter, Zacks reports.

Briacell Therap Price Performance

Shares of BCTX stock traded down $0.02 during trading hours on Tuesday, reaching $3.07. The company had a trading volume of 301,364 shares, compared to its average volume of 373,176. Briacell Therap has a 12 month low of $2.93 and a 12 month high of $36.00. The business has a fifty day simple moving average of $3.91 and a 200-day simple moving average of $5.44. The company has a market cap of $26.71 million, a price-to-earnings ratio of -0.13 and a beta of 1.21.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC purchased a new stake in shares of Briacell Therap (NASDAQ:BCTX) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap at the end of the most recent quarter. 15.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BCTX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. Wall Street Zen upgraded Briacell Therap from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.